A Prospective Observational Cohort Study to Understand Asthma in China with Long-Term Follow-Up and Biomarker Analysis

What this Trial Is About

Researchers are conducting a prospective observational study to establish a standardized asthma cohort in China, involving 400 patients diagnosed with asthma according to the 2023 GINA criteria. The study aims to build an information network platform and a biospecimen bank to observe asthma outcomes and identify biomarkers that may predict these outcomes. The research is designed to explore the mechanisms behind asthma and find treatable traits related to disease progression. Participants will undergo diagnostic tests such as lung function tests, chest CT scans, induced sputum analysis, blood routine tests, IgE tests, FeNO tests, six-minute walk tests, and complete asthma-related questionnaires. These procedures follow routine diagnosis and treatment protocols. Blood samples will be collected and sent to designated laboratories for storage and biomarker analysis. No additional investigational drugs will be administered during the study. Patients will be followed for two or more years, with baseline and follow-up data collected regularly. Outcome measures include the Asthma Control Test ACT, Asthma Control Questionnaire ACQ, and induced sputum analysis over two years. Researchers will monitor prognosis prediction related to specific treatment regimens. Data will be entered electronically and on paper questionnaires, with oversight by the principal investigator and analysis by a dedicated epidemiology and statistics team. The total participation duration is at least two years.

The Cohort Study for Asthma in China